Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers
Vishal Navani(Hunter Medical Research Institute), André van der Westhuizen(Hunter Medical Research Institute), Hiren Mandaliya(Lake Macquarie Private Hospital), Moira C. Graves(Hunter Medical Research Institute), Nikola A. Bowden(Hunter Medical Research Institute), Giovana Celli Marchett(Calvary Mater Newcastle Hospital)
Cited by 10
Related Papers
BCL-2 family isoforms in apoptosis and cancer
|Cell Death and Disease|2019|706
Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
|Translational Lung Cancer Research|2019|392
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
|Journal of Clinical Oncology|2022|166
Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
|Journal of Clinical Medicine|2020|30
Whole genome amplification and its impact on CGH array profiles
|BMC Research Notes|2008|24